Form 4: Soleno Therapeutics Merger Completes, Executive Sells Shares

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., with executive Matthew Pauls reporting changes in beneficial ownership.

Summary

• Matthew Pauls, a Director at Soleno Therapeutics Inc., reported a transaction on May 18, 2026, related to the company's merger.
• The merger involved Soleno Therapeutics, Inc., Neocrine Biosciences, Inc. (Parent), and Sigma Merger Sub, Inc. (Merger Sub).
• Following the merger, each outstanding share of Soleno Therapeutics' common stock was converted into the right to receive $53.00 in cash.
• Previously reported restricted stock units (RSUs) were also cancelled and converted into the right to receive $53.00 in cash per unit.
• An option to buy common stock with an exercise price of $4.60 was cancelled in exchange for a cash payment representing the difference between the merger consideration and the exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on a completed merger and the resulting cash conversion of securities, with no new financial performance data or future guidance.

Positives

• The merger was successfully completed, providing a cash payout of $53.00 per share to common stockholders.
• Vested and unvested RSUs were converted into cash, offering a clear financial outcome for RSU holders.
• Stock options were also converted into a cash payment, realizing value for option holders.

Negatives

• The company's common stock will cease to be publicly traded as a result of the merger.
• The transaction represents a change of control and potential delisting from public markets.

Risks

• The filing does not explicitly detail risks associated with the merger completion itself, but typical risks include integration challenges and potential regulatory hurdles.
• Shareholders who held options may have realized less value than anticipated if the merger consideration was not significantly higher than the exercise price.

Future Outlook

The filing primarily reports on a completed transaction (merger) and associated changes in beneficial ownership. Future outlook for the combined entity is not detailed in this specific filing, but the transaction implies a transition to private ownership under Neocrine Biosciences, Inc.

Management Comments

• Matthew Pauls, Director, reported transactions related to the merger.
• The merger was executed under an Agreement and Plan of Merger dated April 5, 2026.

Industry Context

StockSavvy.ai notes that the completion of this merger signifies consolidation within the biotechnology or pharmaceutical sector, a trend driven by the pursuit of pipeline synergies and market expansion. The cash-out structure suggests a strategic acquisition rather than a stock-for-stock combination.

Stakeholder Impact

• Shareholders: Will receive $53.00 in cash for each share of common stock held.
• RSU Holders: Will receive $53.00 in cash for each vested and unvested RSU.
• Option Holders: Will receive a cash payment based on the difference between the merger consideration and their option exercise price.
• Employees: May experience changes in employment terms or roles under the new ownership of Neocrine Biosciences, Inc.

Next Steps

• Soleno Therapeutics, Inc. will continue as a wholly owned subsidiary of Neocrine Biosciences, Inc.
• Shareholders and option holders will receive cash payments as per the merger agreement.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Neocrine Biosciences, Matthew Pauls, SEC Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Cash Consideration